Life Biosciences
PrivateLast Round
Series D
Apr 8, 2026
Est. Valuation
$500M
Total Funding Raised
$212M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Life Biosciences is a biotechnology company that develops drug therapies aimed at enhancing the quality of life for aging individuals by addressing the systemic health decline associated with aging and combating age-related diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Life Biosciences Comparables
Compare Life Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NewLimit | 85% | |
| Cambrian Bio | 81% | |
| Turn Biotechnologies | 81% |
Life Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Apr 8, 2026 | ||||
| Series C | Jan 5, 2022 | ||||
| Series B | Jan 15, 2019 |
Life Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Longevity Fund | Series C |
| McKenny-McFarlane Capital | Series C |
| The Venture Collective | Series C |
| Alpha Wave Global | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors increased 154% MoM, reaching 47.8K.
- Apr 16, 2026
Monthly visitors grew 92% MoM.
Recent news
Latest coverage and updates
- acquiresOct 14, 2026
Life Biosciences, Inc. later acquires Lua, according to the company history.
- is_developingOct 9, 2026
In Jan '26, regulators in the United States clear Life Biosciences, Inc. to test ER-100, an experimental treatment designed to rejuvenate damaged eye cells; early human trials are underway, but efficacy remains unproven.
- attends_eventOct 1, 2026
Life Biosciences, Inc. will present new interim data from its Phase 1 ER-100 trial in patients with glaucoma during an oral session at Eyecelerator @ American Academy of Ophthalmology (AAO) 2026 in Louisiana on Oct 8th '26.
- hiresAug 10, 2026
Life Biosciences, Inc. appoints Stephen Webster to its Board of Directors, effective Aug 1st '26, bringing biotechnology finance, commercialization, and governance expertise.
Life Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Life Biosciences's valuation, stock price, and market status.
Is Life Biosciences a public or private company?
Life Biosciences is a private company.
What is the current stock price of Life Biosciences?
Life Biosciences is a private company, so its shares have no public market price. Caplight tracks Life Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Life Biosciences worth (valuation)?
Life Biosciences's valuation is estimated at $500.0M based on funding round data.
Can I buy Life Biosciences stock?
Life Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Life Biosciences's last funding round?
Life Biosciences's most recent funding round was Series D on April 8, 2026.
Who are the main investors in Life Biosciences?
Key investors in Life Biosciences include Alpha Wave Global.
Will Life Biosciences IPO soon?
No public IPO plans have been announced for Life Biosciences.
How can I track Life Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Life Biosciences's shares on secondary markets.